Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

BACKGROUND. Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib’s safety pro...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Verma, Sunil, Bartlett, Cynthia Huang, Schnell, Patrick, DeMichele, Angela M., Loi, Sherene, Ro, Jungsil, Colleoni, Marco, Iwata, Hiroji, Harbeck, Nadia, Cristofanilli, Massimo, Zhang, Ke, Thiele, Alexandra, Turner, Nicholas C., Rugo, Hope S.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AlphaMed Press 2016
विषय:
Breast Cancer
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061543/
https://ncbi.nlm.nih.gov/pubmed/27368881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0097
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन